PDF
ePub
Citation
Print
Abstract
Osteoporosis is a common and significant health problem in more than 1/3 of postmenopausal women. Strategies for the medical treatment of osteoporosis are primarily based on decreasing the resorption component of bone turnover by estrogen, alendronate, risedronate, raloxifene, or calcitonine. Recently there are therapies that are focused on increasing bone formation by fluoride, parathyroid hormone, or strontium ranelate. This article reviews the medical treatment of osteoporosis focusing on the pharmacokinetic effects on the bone metabolism, anti-fracture effects, usage of the drugs and their side effects.
References
1. Miller PD. The treatment of osteoporosis. Antiresorptive therapy. Clin Lab Med. 2000. 20:603–622.
2. Writing group for the Women's Health initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:Principal results from the Womens Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.
3. Dennis MB, Desmond ET, Douglas CB, Kris E, Thomas M, Steven RC, et al. Fracture risk reduction with alendronate in women with osteoporosis:The fracture intervention trial. J Clin Endocrinol Metab. 2000. 85:4118–4124.
4. Steven TH, Nelson BW, Harry KG, Clark DM, Thomas H, Paul DM, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999. 282:1344–1352.
5. Elizabeth BC, Deborah G, Andreas S, Pamela WA, David AC, Kristine DH, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA. 2002. 287:847–857.
6. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Reginster JY, et al. The effects of strontium ranelate on the risk of vertebralfracture in women with postmenopausal osteoporosis. N Engl J Med. 2004. 350:459–468.
XML Download